Skip to main content
. Author manuscript; available in PMC: 2021 Sep 17.
Published in final edited form as: Cancer Treat Res Commun. 2020 Sep 17;25:100210. doi: 10.1016/j.ctarc.2020.100210

Table 1.

Serum levels of key hepatic, cardiac, and kidney metabolites.

AST [IU/L] ALT [IU/L] BUN [mg/dL] Albumin [g/dL] Glucose [mg/dL] Total Protein [g/dL]
ref (54–269) ref (26–77) ref (12–28) ref (2.8–3.8) ref (62–175) ref (4.8–7.0)
Control 187.7 ± 71.6 40.0 ± 22.8 24.4 ± 3.6 2.9 ± 0.1 168 ± 38 4.9 ± 0.4
Mito-MGN 320.0 ± 37.0 58.7 ± 25.4 24.5 ± 3.9 2.7 ± 0.1 159.7 ± 18.6 4.7 ± 0.3

Serum levels assayed in control, non-tumor-bearing C57BL6 mice treated on three times per week for four weeks and serum obtained on day 31. AST, aspartate aminotransferase; ALT, alanine transaminase; BUN, blood urea nitrogen; ref, reference values. Values are mean ± SD, n = 3–5 individual mice.